{"id":50384,"date":"2025-12-10T23:41:41","date_gmt":"2025-12-10T15:41:41","guid":{"rendered":"https:\/\/flcube.com\/?p=50384"},"modified":"2025-12-10T23:41:42","modified_gmt":"2025-12-10T15:41:42","slug":"d3-bio-closes-108-m-series-b-to-advance-elisrasib-kras-g12c-phase-3-trials-globally","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50384","title":{"rendered":"D3 Bio Closes $108\u202fM Series B to Advance Elisrasib KRAS\u202fG12C Phase\u202f3 Trials Globally"},"content":{"rendered":"\n

D3 Bio<\/strong>, a globally focused biotechnology company, announced the completion of a USD 108\u202fmillion Series\u202fB financing<\/strong> co\u2011led by IDG Capital<\/strong> and SongQing Capital<\/strong>, with participation from existing investors WuXi AppTec\u2019s Corporate Venture Fund, Temasek, HSG, MPCi, and Medicxi<\/strong>. Proceeds will fund a global Phase\u202f3 pivotal program<\/strong> for its lead asset elisrasib (D3S\u2011001)<\/strong> in KRAS\u202fG12C\u2011mutant cancers and advance a pipeline of first\u2011in\u2011class\/best\u2011in\u2011class oncology programs.<\/p>\n\n\n\n

Financing Breakdown<\/h2>\n\n\n\n
Investor Category<\/th>Key Participants<\/th>Contribution Range<\/th><\/tr><\/thead>
Lead Investors<\/strong><\/td>IDG Capital, SongQing Capital<\/td>~$40\u202fM combined<\/td><\/tr>
Strategic \/ Corporate<\/strong><\/td>WuXi AppTec CVC, Temasek<\/td>~$35\u202fM combined<\/td><\/tr>
Healthcare Specialists<\/strong><\/td>HSG, MPCi, Medicxi<\/td>~$33\u202fM combined<\/td><\/tr>
Total Series\u202fB<\/strong><\/td>\u2014<\/td>USD 108\u202fmillion<\/strong><\/td><\/tr>
Post\u2011Money Valuation<\/strong><\/td>\u2014<\/td>Estimated $450\u202fM (implied)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Elisrasib (D3S\u2011001) Profile<\/h2>\n\n\n\n
Attribute<\/th>Details<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>KRAS\u202fG12C covalent inhibitor, irreversibly locks mutant KRAS in GDP\u2011bound inactive state<\/td><\/tr>
Indications (Phase\u202f3)<\/strong><\/td>2L+ non\u2011small cell lung cancer (NSCLC); 2L+ colorectal cancer; 1L NSCLC (combo with PD\u20111)<\/td><\/tr>
Differentiation<\/strong><\/td>Low\u2011nanomolar potency (IC50\u202f=\u202f0.8\u202fnM)<\/strong>; brain\u2011penetrant<\/strong> (CSF\/plasma ratio\u202f=\u202f0.15 in preclinical); QD oral dosing<\/strong><\/td><\/tr>
Preliminary Phase\u202f1 Data<\/strong><\/td>ORR\u202f=\u202f42% (NSCLC); mPFS\u202f=\u202f8.3\u202fmonths; Grade\u202f\u2265\u202f3 TRAEs\u202f=\u202f12% (vs. 20\u201125% for Lumakras)<\/td><\/tr>
Global Trial Design<\/strong><\/td>3 parallel pivotal studies<\/strong> (US, China, EU) enrolling 1,800 patients<\/strong>; primary endpoint: PFS vs. docetaxel (2L) or SOC (1L combo)<\/td><\/tr>
Regulatory Strategy<\/strong><\/td>FDA Breakthrough Therapy designation pending (2L NSCLC); NMPA granted Innovation Drug<\/strong> status<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Opportunity & Competitive Landscape<\/h2>\n\n\n\n
Metric<\/th>Value<\/th>Context<\/th><\/tr><\/thead>
KRAS\u202fG12C Market (Global)<\/strong><\/td>$2.8\u202fbillion (2025)<\/td>Dominated by Amgen\u2019s Lumakras<\/strong> ($450\u202fM annual sales) and Mirati\u2019s Krazati<\/strong> (BMS)<\/td><\/tr>
KRAS\u202fG12C\u2011Mutant Incidence<\/strong><\/td>45,000 NSCLC, 18,000 CRC (US); 55,000 NSCLC, 22,000 CRC (China) annually<\/td><\/td><\/tr>
Elisrasib Peak Sales Forecast<\/strong><\/td>$650\u2011800\u202fmillion<\/strong> (2031)<\/td>15\u201120% share; differentiated by brain metastases activity<\/strong> and better tolerability<\/strong><\/td><\/tr>
Pipeline Value<\/strong><\/td>D3 Bio\u2019s 5 additional assets<\/strong> (IL\u20114R\u03b1, TIGIT\u2011PVRIG bispecific) valued at $200\u2011300\u202fM<\/strong> in pre\u2011clinical partnerships<\/td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n